MLTX

MoonLake Immunotherapeutics

55.13 USD
-4.79 (-7.99%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

MoonLake Immunotherapeutics stock is down -0.49% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 7 PUTs, 3 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
02 Feb 20:38 17 May, 2024 55.00 PUT 197 1637
14 Feb 18:04 15 Mar, 2024 70.00 CALL 50 428
14 Feb 19:50 15 Mar, 2024 60.00 PUT 100 301
14 Feb 19:53 15 Mar, 2024 60.00 PUT 85 301
15 Feb 17:41 19 Apr, 2024 65.00 CALL 1000 0
15 Feb 17:43 15 Mar, 2024 60.00 PUT 100 487
16 Feb 19:05 17 May, 2024 40.00 PUT 150 32
16 Feb 19:05 17 May, 2024 40.00 PUT 250 32
16 Feb 19:44 17 May, 2024 40.00 PUT 108 32
20 Feb 19:12 15 Mar, 2024 65.00 CALL 300 2888

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, or ankylosing spondylitis.